Estrella Immunopharma, Inc. announced that D. Boral Capital has initiated coverage on the company, assigning a Buy rating with a 12-month price target of $16.00, highlighting the potential of its lead candidate, EB103.
Company Information
Company
Estrella Immunopharma
Location
California, United States
About
Estrella Immunopharma is a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Estrella Immunopharma ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.